<unk> s or<unk> s are a class of androgen receptor ligands that maintain some of the desirable effects of androgens, such as preventing osteoporsis and muscle loss while reducing risks of developing prostate cancer. In the last 1990s, the first nonsteroidal<unk> , an analog of bicalutamide, was discovered. They are intended to have the same kind of effects as androgenic drugs, such as anabolic-androgenic steroids, but be more selective in their action. As of early 2020, there are no<unk> s which have been approved for therapeutic use by the U.S Food and Drug Administration.
Selective androgen receptor modulator
Selective estrogen receptor modulator
Selective estrogen receptor degrader
Selective androgen receptor degrader
Aromatase inhibitor
Steroidal aromatase inhibitor
N-Terminal domain antiandrogen
Antiandrogen